News summary
[Yahong Pharmaceutical: The listing application for hexylamevulinate hydrochloride ointment photodynamic therapy system was accepted] Securities Times e Company NewsSafariSpinSafari, Yahong Pharmaceutical (688176) announced on the evening of May 12 and received approval and issuance from the State Drug AdministrationSafariSpinSafari"Acceptance Notice", the company's product APL-1702 (SafariSpinSafari...
Newsletter text
[Yahong Pharmaceutical: The application for marketing of hexyl parvalinate hydrochloride ointment photodynamic therapy system was accepted] Securities Times e Company News, Yahong Pharmaceutical (688176) announced on the evening of May 12 that it received the "Acceptance Notice" approved and issued by the State Food and Drug Administration ", the company's product APL-1702 (Common name: Hexyl Formalate Hydrochloride Ointment Photodynamic Therapy System) is intended for the treatment of histologically confirmed high-grade squamous intraepithelial lesions of the cervix aged 18 and older who have excluded carcinoma in situSafariSpinSafari,HSIL) patients 'marketing applications were accepted.
